Press Releases


Press Releases

Date Title and Summary
Toggle Summary Foamix Announces Completion of Patient Enrollment in Phase 3 Acne Trials for Minocycline Foam FMX101
Expected to Report Top-Line Results on Schedule in First Half of 2017 REHOVOT, Israel , and BRIDGEWATER, New Jersey , Nov. 28, 2016 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) ("Foamix" or the "Company"), a clinical stage specialty pharmaceutical company focused on developing and
Toggle Summary Foamix Reports Third Quarter 2016 Financial Results and Provides Business Update
Conference Call and Webcast on Wednesday, November 16, 2016 at 8:30am Eastern / 5:30am Pacific REHOVOT, Israel , Nov. 15, 2016 /PRNewswire/ --  Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (" Foamix Pharmaceuticals " or the "Company"), a clinical stage specialty pharmaceutical company focused on
Toggle Summary Foamix Pharmaceuticals to Present at Jefferies London Healthcare Conference on November 17
REHOVOT, Israel and BRIDGEWATER, New Jersey , Nov. 10, 2016 /PRNewswire/ --  Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced
Toggle Summary Foamix Pharmaceuticals to Release Third Quarter 2016 Financial Results and Host Conference Call & Webcast on Wednesday, November 16
REHOVOT, Israel , and BRIDGEWATER, N.J. , Nov. 7, 2016 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced
Toggle Summary Foamix Pharmaceuticals to Present at the 25th Annual Credit Suisse Healthcare Conference on November 7
REHOVOT, Israel and BRIDGEWATER, New Jersey , Nov. 3, 2016  /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced
Toggle Summary Foamix Pharmaceuticals Ltd. Announces Pricing of its $57 Million Follow-on Offering of Ordinary Shares
REHOVOT, Israel and BRIDGEWATER, New Jersey , Sept. 28, 2016 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. ("Foamix") (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Pharmaceuticals Ltd. Announces Proposed Follow-on Offering of Ordinary Shares
REHOVOT, Israel and BRIDGEWATER, N.J. , Sept. 27, 2016 /PRNewswire/ --  Foamix Pharmaceuticals Ltd. ("Foamix") (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea
FMX103 Demonstrated Statistically Significant Improvement Compared with Vehicle in the Main Efficacy Endpoints Conference Call and Webcast Today at 9:00 a.m. Eastern Time REHOVOT, Israel and BRIDGEWATER, N.J. , Sept. 12, 2016 /PRNewswire/ -- Foamix Pharmaceuticals Ltd.
Toggle Summary Foamix to Announce Topline Results in Phase 2 Clinical Trial of FMX-103 Minocycline Topical Foam for Moderate-to-Severe Papulopustular Rosacea
Company to Host Conference Call on Monday, September 12 at 9:00 a.m. Eastern Time REHOVOT, Israel and BRIDGEWATER, N.J. , Sept. 9, 2016 /PRNewswire/ --  Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and
Toggle Summary Foamix to Present Corporate Overview at the Rodman & Renshaw 18th Annual Global Investment Conference
REHOVOT, Israel and BRIDGEWATER, N.J. , Sept. 06, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that Dr.
Toggle Summary Foamix Reports Second Quarter 2016 Financial Results and Provides Business Update
Conference Call and Webcast on Wednesday, August 10, 2016 at 8:30am Eastern / 5:30am Pacific REHOVOT, Israel , Aug. 10, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)   (“Foamix Pharmaceuticals” or the “Company”), a clinical stage specialty pharmaceutical company focused on
Toggle Summary Foamix Pharmaceuticals Second Quarter Financial Results Conference Call & Webcast Scheduled for Wednesday, August 10
REHOVOT, Israel and BRIDGEWATER, N.J. , July 25, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in
Toggle Summary Foamix to Present at the BIO International Convention
REHOVOT, Israel and BRIDGEWATER, N.J. , June 01, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in
Toggle Summary Foamix Pharmaceuticals Announces Publication of Abstract on FDX-104 in the Treatment of EGFRI Induced Rash for the 2016 ASCO Meeting
REHOVOT, Israel and BRIDGEWATER, N.J. , May 31, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that its
Toggle Summary Foamix to Present Corporate Overview at the Jefferies 2016 Healthcare Conference
REHOVOT, Israel and BRIDGEWATER, N.J. , May 26, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that David
Toggle Summary Foamix Names Dr. Stanley Hirsch as Chairman, and Dr. Dalia Megiddo as a Member of the Board of Foamix Pharmaceuticals
REHOVOT, Israel and BRIDGEWATER, N.J. , May 16, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the
Toggle Summary Foamix Reports First Quarter 2016 Financial Results and Provides Business Update
Conference Call and Webcast on Tuesday, May 10, 2016 at 8:00am Eastern / 5:00am Pacific REHOVOT, Israel , May 10, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)   (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and
Toggle Summary Foamix Announces Dosing of First Patient in Phase 3 Acne Studies for Minocycline Foam FMX101
REHOVOT, Israel , and BRIDGEWATER, N.J. , May 09, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that the
Toggle Summary Foamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam (FMX103) for Treatment of Papulopustular Rosacea
REHOVOT, Israel and BRIDGEWATER, N.J. , May 03, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in
Toggle Summary Foamix Pharmaceuticals First Quarter Financial Results Conference Call & Webcast Scheduled for Tuesday, May 10
REHOVOT, Israel and BRIDGEWATER, N.J. , April 28, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in